Table 2.
Clinical and pathology characteristics associated with the metastatic tumors
| M0 (N = 89) | M1 (N = 68) | Total (N = 157) | |
|---|---|---|---|
| Metastatic site | |||
| Contralateral adrenal | 3 (3.4%) | 5 (7.4%) | 8 (5.1%) |
| Ipsilateral adrenal | 2 (2.2%) | 8 (11.8%) | 10 (6.4%) |
| Pancreas | 5 (5.6%) | 2 (2.9%) | 7 (4.5%) |
| Skin | 2 (2.2%) | 2 (2.9%) | 4 (2.5%) |
| Non‐regional nodes | 9 (10.1%) | 1 (1.5%) | 10 (6.4%) |
| Pulmonary | 40 (44.9%) | 20 (29.4%) | 60 (38.2%) |
| Liver | 4 (4.5%) | 5 (7.4%) | 9 (5.7%) |
| Bone | 9 (10.1%) | 10 (14.7%) | 19 (12.1%) |
| Brain | 7 (7.9%) | 4 (5.9%) | 11 (7.0%) |
| Other* | 8 (9.0%) | 11 (16.2%) | 19 (12.1%) |
| Metastatic grade | |||
| 2 | 16 (18.0%) | 13 (19.1%) | 29 (18.5%) |
| 3 | 59 (66.3%) | 36 (52.9%) | 95 (60.5%) |
| 4 | 14 (15.7%) | 19 (27.9%) | 33 (21.0%) |
| Metastatic necrosis | |||
| No | 56 (62.9%) | 38 (55.9%) | 94 (59.9%) |
| Yes | 33 (37.1%) | 30 (44.1%) | 63 (40.1%) |
| Metastatic sarcomatoid | |||
| No | 85 (95.5%) | 62 (91.2%) | 147 (93.6%) |
| Yes | 4 (4.5%) | 6 (8.8%) | 10 (6.4%) |
| PD‐1 IHC in metastatic tumor | |||
| Missing | 2 | 0 | 2 |
| Absent | 23 (26.4%) | 19 (27.9%) | 42 (27.1%) |
| Focal | 29 (33.3%) | 27 (39.7%) | 56 (36.1%) |
| Moderate | 21 (24.1%) | 17 (25.0%) | 38 (24.5%) |
| Marked | 14 (16.1%) | 5 (7.4%) | 19 (12.3%) |
| PD‐L1 IHC in metastatic tumor | |||
| Missing | 0 | 1 | 1 |
| Absent | 77 (86.5%) | 60 (89.6%) | 137 (87.8%) |
| Present | 12 (13.5%) | 7 (10.4%) | 19 (12.2%) |
*
Other includes thyroid, bowel, spleen, muscle, omentum, heart, etc